journal
https://read.qxmd.com/read/2891441/phase-i-trial-of-taxol-in-patients-with-advanced-cancer
#1
JOURNAL ARTICLE
R C Donehower, E K Rowinsky, L B Grochow, S M Longnecker, D S Ettinger
Taxol is a unique plant-derived antineoplastic agent that appears to exert its cytotoxic effect by interfering with microtubule structure and function. In this phase I trial, in which the drug was given as a brief iv infusion every 3 weeks, the dose-limiting toxicity was leukopenia, with thrombocytopenia being seen much less frequently. Sensory neuropathy was frequently seen at the highest dosage, with numbness and paresthesias appearing in a glove-and-stocking distribution. In some cases, this appeared to be a cumulative effect...
December 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2825994/etoposide-ifosfamide-and-cisplatin-in-the-treatment-of-advanced-non-small-cell-lung-cancer
#2
JOURNAL ARTICLE
A Ardizzoni, V Fusco, M Gulisano, P Pronzato, F Baracco, A Capaccio, G Pastorino, M Nosenzo, R Felletti, F Fabiano
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2446754/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-colorectal-carcinoma-a-southwest-oncology-group-study
#3
JOURNAL ARTICLE
W H Harvey, T R Fleming, D D Von Hoff, J G Katterhagen, C A Coltman
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2446753/phase-ii-trial-of-fludarabine-phosphate-in-patients-with-head-and-neck-cancer-a-southwest-oncology-group-study
#4
JOURNAL ARTICLE
G B Weiss, B Metch, D D Von Hoff, S A Taylor, J H Saiers
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3677115/oral-gestrinone-a-novel-antiprogestin-with-no-antitumor-activity-in-endocrine-sensitive-breast-cancer
#5
JOURNAL ARTICLE
D Cunningham, J C Gazet, H T Ford, R C Coombes
We have treated 15 patients with locally advanced or metastatic breast cancer using the synthetic 19-norsteroid gestrinone (2.5 mg orally every 3 days). All patients had assessable disease and endocrine-sensitive tumors, as defined by a previous positive response to endocrine therapy. There were no objective responses. Six patients had disease stabilization and nine had progressive disease on treatment. Seven patients were given endocrine therapy after gestrinone and three have responded. Gestrinone has no significant antitumor activity in hormone-sensitive breast cancer...
November 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3677112/management-of-learned-food-aversions-in-cancer-patients-receiving-chemotherapy
#6
JOURNAL ARTICLE
R D Mattes, C Arnold, M Boraas
Aversions that form towards foods after their ingestion has been associated with illness are termed learned food aversions (LFA). This adverse treatment side effect has been implicated in the anorexia of cancer and can compromise the quality of patients' lives. In an attempt to block the formation or ameliorate the manifestations of this treatment sequela, a nutritionally inconsequential "scapegoat" food was presented to patients just prior to their first course of therapy. The hypothesis was that treatment-related aversions would be targeted towards the scapegoat, thereby sparing acceptable and nutrient-dense items in the patient's typical diet...
November 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2445482/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-hepatoma-a-southwest-oncology-group-study
#7
JOURNAL ARTICLE
W H Harvey, T R Fleming, G Beltran, J H Saiers, N Oishi, D D Von Hoff
No abstract text is available yet for this article.
November 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3477318/effectiveness-of-scalp-cooling-in-reducing-alopecia-caused-by-epirubicin-treatment-of-advanced-breast-cancer
#8
COMPARATIVE STUDY
M H Robinson, A C Jones, K D Durrant
The value of scalp cooling in the prevention of alopecia was investigated in 32 patients with advanced breast cancer who were given a mean of four courses of 40-80 mg/m2 of epirubicin. None of the 15 patients free from liver metastases who received scalp cooling required a wig, whereas four of eight similar patients who did not receive scalp cooling did require a wig. Abnormalities of aspartate transaminase and alkaline phosphatase pretreatment were predictive for reduced efficacy of scalp cooling, but not a contraindication to its use...
October 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3308078/gallium-nitrate-in-prostatic-cancer-evaluation-of-antitumor-activity-and-effects-on-bone-turnover
#9
JOURNAL ARTICLE
H I Scher, T Curley, N Geller, D Dershaw, E Chan, J Nisselbaum, N Alcock, P Hollander, A Yagoda
Gallium nitrate, an agent known to inhibit bone resorption, was evaluated in patients with bidimensionally measurable hormone-refractory prostatic cancer. The starting dose was 200 mg/m2 iv by continuous infusion over 7 days. Two patients (10%; 95% confidence limits, 0%-22%) achieved short partial remissions of 1 and 6+ months, while seven of 23 (30%; 95% confidence limits, 14%-52%) showed a diminution of bone pain. Serial indices of bone turnover including serum calcium, phosphorus, and urinary hydroxyproline excretion showed a significant decrease at the completion of the infusion which returned to baseline prior to the next cycle...
October 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3115570/phase-i-trial-of-combinations-of-recombinant-interferons-beta-ser-and-gamma-in-patients-with-advanced-malignancy
#10
JOURNAL ARTICLE
J H Schiller, B Storer, J K Willson, E C Borden
Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-beta ser and IFN-gamma in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-gamma, followed by a 10-minute iv injection of IFN-beta ser, three times a week. Patients were entered on fixed dose levels of 1 X 10(6), 3 X 10(6), 10 X 10(6), 30 X 10(6), and 100 X 10(6) units of each IFN...
October 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2820573/unexpected-toxicity-encountered-in-the-national-wilms-tumor-study
#11
LETTER
G J D'Angio
No abstract text is available yet for this article.
October 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3038318/phase-ii-trial-of-oral-piritrexim-bw301u-in-patients-with-stage-iii-non-small-cell-lung-cancer
#12
JOURNAL ARTICLE
M G Kris, R J Gralla, M T Burke, L D Berkowitz, L D Marks, D P Kelsen, R T Heelan
No abstract text is available yet for this article.
July 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3552221/indicine-n-oxide-clinical-use-of-a-pyrrolizidine-alkaloid
#13
REVIEW
S A King, M Suffness, B Leyland-Jones, D F Hoth, P J O'Dwyer
No abstract text is available yet for this article.
May 1987: Cancer Treatment Reports
https://read.qxmd.com/read/2436773/evaluation-of-fludarabine-phosphate-in-renal-cell-carcinoma-a-southwest-oncology-group-study
#14
JOURNAL ARTICLE
L Balducci, B Blumenstein, D D Von Hoff, M Davis, H E Hynes, R M Bukowski, E D Crawford
No abstract text is available yet for this article.
May 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3815401/phase-ii-studies-of-pcnu-and-bisantrene-in-advanced-renal-cell-carcinoma
#15
JOURNAL ARTICLE
P J Elson, R H Earhart, L K Kvols, R Spiegel, A M Keller, M S Kies, T E Davis, C Stevens, L Gumas, D L Trump
No abstract text is available yet for this article.
March 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3815391/weekly-5-fluorouracil-combined-with-pala-toxic-and-therapeutic-effects-in-colorectal-cancer
#16
JOURNAL ARTICLE
F M Muggia, F J Camacho, B H Kaplan, M D Green, E S Greenwald, J C Wernz, P F Engstrom
A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU...
March 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3493069/chemoendocrine-therapy-with-prolonged-estrogen-priming-in-advanced-breast-cancer-endocrine-pharmacokinetics-and-toxicity
#17
JOURNAL ARTICLE
C Benz, D Gandara, B Miller, T Drakes, S Monroe, B Wilbur, M DeGregorio
Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals...
March 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3802121/allergy-induced-hepatic-toxicity-associated-with-dacarbazine
#18
JOURNAL ARTICLE
E McClay, C J Lusch, M J Mastrangelo
No abstract text is available yet for this article.
February 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3542207/hammering-away-at-solid-tumors
#19
JOURNAL ARTICLE
F R Appelbaum
No abstract text is available yet for this article.
February 1987: Cancer Treatment Reports
https://read.qxmd.com/read/3100034/phase-ii-trial-of-ifosfamide-in-children-with-malignant-solid-tumors
#20
JOURNAL ARTICLE
C B Pratt, M E Horowitz, W H Meyer, E Etcubanas, E I Thompson, E C Douglass, J A Wilimas, F A Hayes, A A Green
Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years. In this phase II study, all patients received 1.6 g/m2/day X 5 iv over 15 minutes followed by mesna at a dose of 400 mg/m2 iv at 15 minutes and 4 and 6 hours after ifosfamide. Responses were observed in five of 15 patients with osteosarcoma, two of ten with neuroblastoma, two of six with Wilms' tumor, two of five with rhabdomyosarcoma, four of eight with other soft tissue sarcomas, one of one with retinoblastoma, one of two with germ cell tumors, one of one with B-cell lymphoma, and one of one with a primitive neuroectodermal tumor...
February 1987: Cancer Treatment Reports
journal
journal
26734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.